Home > Insider Trading > Filing (0000899243-16-015630)

Filing Details

Accession Number:: 0000899243-16-015630
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2016-03-09 16:32:09
Reporting Period:: 2016-03-07

Filing Date:: 2016-03-09
Accepted Time:: 2016-03-09 16:32:09
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1369868	China Biologic Products Inc.	CBPO	Biological Products, (No Disgnostic Substances) (2836)	752308816

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1635357	Min Fang	C/O Cbpo, 18/F, Jialong International Building, 19 Chaoyang Park Road Beijing F4 100125		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2016-03-07	4,257,000	$107.00	4,087,200	No	4	S	Indirect	See footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See footnotes

Footnotes

The shares of common stock, $0.0001 par value per share (the "Common Stock") reported in Column 4 of this Form 4 were sold pursuant to that certain amended and restated underwriting agreement dated March 2, 2016 (the "Underwriting Agreement"), entered into by and among China Biologic Products, Inc. (the "Issuer"), Warburg Pincus Private Equity X, L.P., a Delaware limited partnership ("WP X"), Warburg Pincus X Partners, L.P., a Delaware limited partnership ("WPP X," together with WP X, the "Funds") and Morgan Stanley & Co. International plc, as the underwriter named in the Underwriting Agreement (the "Underwriter"). At the closing of the transaction contemplated under the Underwriting Agreement, on March 7, 2016, the Funds sold an aggregate of 4,257,000 shares of Common Stock to the Underwriter for a purchase price of $455,499,000.00, or $107.00 per share.
The 4,087,200 shares of the Common Stock of the Issuer are held by WP X Biologics LLC, a Delaware limited liability company ("WP X B"), WP X and holder of 96.9% of the equity interest in WP X B, and WPP X and holder of 3.1% of the equity interest in WP X B. Warburg Pincus X, L.P., a Delaware limited partnership ("WP X LP"), is the general partner of each of the Funds, Warburg Pincus X GP L.P., a Delaware limited partnership ("WP X GP"), is the general partner of WP X LP, WPP GP LLC, a Delaware limited liability company ("WPP GP"), is the general partner of WP X GP, Warburg Pincus Partners, L.P., a Delaware limited partnership ("WP Partners"), is the managing member of WPP GP, Warburg Pincus Partners GP LLC, a Delaware limited liability company ("WPP GP LLC"),
(Continued from Footnote 2) is the general partner of WP Partners, Warburg Pincus & Co., a New York limited liability company, is the managing member of WPP GP LLC, and Warburg Pincus LLC, a New York limited liability company ("WP LLC"), manages each of the Funds.
Mr. Fang is a Managing Director and Member of WP LLC. As such, Mr. Fang may be deemed to have an indirect pecuniary interest (within the meaning of Rule 16a-1 under the Securities and Exchange Act of 1934, as amended (the "Exchange Act")) in an indeterminate portion of the securities reported as beneficially owned by the Funds and WP X B. Mr. Fang disclaims beneficial ownership of such securities, except to the extent of any direct pecuniary interest therein. Mr. Fang does not directly own any shares of Common Stock of the Issuer.